Aclaris Therapeutics, Inc.
NASDAQ: ACRS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Neal S. Walker
- Employees
- 61
- Headquarters
- Wayne, United States
- IPO year
- 2015
- Market cap
- $577.7M
- Website
- https://www.aclaristx.com
Loading ACRS…
Loading profile data…Frequently asked questions about ACRS
What does Aclaris Therapeutics, Inc. (ACRS) do?
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progr...
Where does ACRS trade?
Aclaris Therapeutics, Inc. (ACRS) trades on the NASDAQ Global Select.
What sector is ACRS in?
Aclaris Therapeutics, Inc. (ACRS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Aclaris Therapeutics, Inc.?
Neal S. Walker is the chief executive officer of Aclaris Therapeutics, Inc. (ACRS).
Where is Aclaris Therapeutics, Inc. headquartered?
Aclaris Therapeutics, Inc. is headquartered in United States.
Does ACRS pay a dividend?
Aclaris Therapeutics, Inc. (ACRS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ACRS go public?
Aclaris Therapeutics, Inc. (ACRS) completed its initial public offering in 2015.